ArticleAsian journal of pharmaceutical sciences2021
Rapid and effective treatment of traumatic spinal cord injury using stem cell derived exosomes.
Article in Asian journal of pharmaceutical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 3 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Stem Cell-Derived Exosomes: A Comprehensive Review of Biomedical Applications, Challenges, and Future Directions.International journal of nanomedicine · 2025Pooled it
- Stem cell-derived exosome treatment for acute spinal cord injury: a systematic review and meta-analysis based on preclinical evidence.Frontiers in neurology · 2025Pooled it
- Efficacy of miRNA-modified mesenchymal stem cell extracellular vesicles in spinal cord injury: A systematic review of the literature and network meta-analysis.Frontiers in neuroscience · 2022Pooled it
- A dual-functional engineered exosome-laden hydrogel redirects endogenous neural stem cell fate for spinal cord injury repair.Bioactive materials · 2026Article
- Recent Advances in Diversified Materials for Spinal Cord Injury Repair and Regeneration.Gels (Basel, Switzerland) · 2026Review
- The SHEDs-derived apoptotic bodies for inflammatory regulation in spinal cord repair.NPJ Regenerative medicine · 2026Article
- Mitophagy: A key regulator in the pathophysiology and treatment of spinal cord injury.Neural regeneration research · 2026Article
- Extracellular vesicle-based therapeutic strategies for spinal cord injury.Extracellular vesicles and circulating nucleic acids · 2026Review
- Exosome-Based Therapeutics for Musculoskeletal Disorders: Advances in Engineering, Targeting, and Biomaterial Integration.ACS nano · 2025Review
- Extracellular Vesicles as Emerging Therapeutic Strategies in Spinal Cord Injury: Ready to Go.Biomedicines · 2025Review
- Review
- Insights into Astrogliosis, Inflammation Processes, and Emerging Treatments by Exosome Therapy and Low-Level Laser Therapy for Spinal Cord Injury: A Systematic Review.Journal of lasers in medical sciences · 2025Review
- Exosome-Loaded Bioscaffolds for Spinal Cord Injuries: A Review.Stem cells international · 2025Review
- Bibliometric Analysis of Exosome Research in Spinal Cord Injury (2000-May 2024). Trends, Collaborations, and Emerging Insights.Drug design, development and therapy · 2025Article
- Exosomes-Based Nanotherapeutic Strategies: An Important Approach for Spinal Cord Injury Repair.International journal of nanomedicine · 2025Review
- Review
- Exosomes as therapeutic and drug delivery vehicle for neurodegenerative diseases.Journal of nanobiotechnology · 2024Review
- Advances in extracellular vesicle-based combination therapies for spinal cord injury.Neural regeneration research · 2024Review
- Exosome-mediated repair of spinal cord injury: a promising therapeutic strategy.Stem cell research & therapy · 2024Review
- A New Paradigm in Spinal Cord Injury Therapy: from Cell-free Treatment to Engineering Modifications.CNS & neurological disorders drug targets · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traumatic spinal cord injury is a fatal acute event without effective clinical therapies. Following the trauma, immediate neural protection and microenvironment mitigation are vitally important for nerve tissue repair, where stem cell-based therapies could be eclipsed by the deficiency of cells due to the hostile microenvironment as well as the transport and preservation processes. Effective emergency strategies are required to be convenient, biocompatible, and stable. Herein, we assess an emergency cell-free treatment using mesenchymal stem cell-derived exosomes, which have proven capable of comprehensive mitigation of the inhibitory lesion microenvironment. The clinically validated fibrin glue is utilized to encapsulate the exosomes and in-situ gelates in transected rat spinal cords to provide a substrate for exosome delivery as well as nerve tissue growth. The emergency treatment alleviates the inflammatory and oxidative microenvironment, inducing effective nerve tissue repair and functional recovery. The therapy presents a promising strategy for effective emergency treatment of central nervous system trauma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.